Verastem Oncology
Needham
About Verastem Oncology
Verastem Oncology is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $626.6M
- Funding stage: IPO
- Last round: Post-IPO Equity (Nov 2025)
- Ticker: nasdaq:VSTM
- Website: verastem.com
- Phone: 1-781-292-4200
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/verastem-oncology-23080 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.